Absi Corp (NASDAQ:ABSI), Recursion Pharma (NASDAQ:RXRX), Schrodinger (NASDAQ:SDGR), and Certara (NASDAQ:CERT) are ...

We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Twitter by Jack Prescott. In this article, we will ...

VANCOUVER, British Columbia, January 13, 2025--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the ...

KeyBanc lowered the firm’s price target on AbCellera (ABCL) to $4 from $5 and keeps an Overweight rating on the shares. The firm believes there are several key themes that should play out this ...

1 Day ABCL -1.14% DJIA -0.32% S&P Mid Cap 400 -0.08% Health Care/Life Sciences -0.52% ...

AbCellera is expanding its collaboration with pharmaceutical company AbbVie to include the discovery of T-cell engagers in oncology. The new agreement will see the Canadian developer of antibody ...

We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Twitter by Jack Prescott. In this article, we will summarize the bulls’ thesis on ABCL. AbCellera Biologics Inc. (ABCL ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T-cell engagers (TCE) in oncology. The expansion ...